519 related articles for article (PubMed ID: 21167777)
1. The late complications of totally implantable central venous access ports: the results from an Italian multicenter prospective observation study.
Dal Molin A; Rasero L; Guerretta L; Perfetti E; Clerico M
Eur J Oncol Nurs; 2011 Dec; 15(5):377-81. PubMed ID: 21167777
[TBL] [Abstract][Full Text] [Related]
2. Totally implantable venous access port systems and risk factors for complications: a one-year prospective study in a cancer centre.
Narducci F; Jean-Laurent M; Boulanger L; El Bédoui S; Mallet Y; Houpeau JL; Hamdani A; Penel N; Fournier C
Eur J Surg Oncol; 2011 Oct; 37(10):913-8. PubMed ID: 21831566
[TBL] [Abstract][Full Text] [Related]
3. Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumours: experience from 178 cases using a single type of device.
Biffi R; Corrado F; de Braud F; de Lucia F; Scarpa D; Testori A; Orsi F; Bellomi M; Mauri S; Aapro M; Andreoni B
Eur J Cancer; 1997 Jul; 33(8):1190-4. PubMed ID: 9301441
[TBL] [Abstract][Full Text] [Related]
4. Totally implantable venous access ports: retrospective review of long-term complications in 81 patients.
Bassi KK; Giri AK; Pattanayak M; Abraham SW; Pandey KK
Indian J Cancer; 2012; 49(1):114-8. PubMed ID: 22842178
[TBL] [Abstract][Full Text] [Related]
5. Risk of thrombosis and infections of central venous catheters and totally implanted access ports in patients treated for cancer.
Beckers MM; Ruven HJ; Seldenrijk CA; Prins MH; Biesma DH
Thromb Res; 2010 Apr; 125(4):318-21. PubMed ID: 19640573
[TBL] [Abstract][Full Text] [Related]
6. [Subcutaneous chamber systems (ports) for long-term care in cancer patients].
Hájek R; Sevcík P; Ondrásek J; Mayer J; Vásová I; Král Z; Tomíska M; Krahulcová E; Penka M; Kubesová H
Vnitr Lek; 1995 Jan; 41(1):21-7. PubMed ID: 7716888
[TBL] [Abstract][Full Text] [Related]
7. Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days.
Biffi R; de Braud F; Orsi F; Pozzi S; Mauri S; Goldhirsch A; Nolè F; Andreoni B
Ann Oncol; 1998 Jul; 9(7):767-73. PubMed ID: 9739444
[TBL] [Abstract][Full Text] [Related]
8. Comparison of totally implanted reservoirs with external catheters as venous access devices in pediatric oncologic patients.
Ross MN; Haase GM; Poole MA; Burrington JD; Odom LF
Surg Gynecol Obstet; 1988 Aug; 167(2):141-4. PubMed ID: 3400032
[TBL] [Abstract][Full Text] [Related]
9. Totally implantable central venous access ports. Analysis of 700 cases.
Barbetakis N; Asteriou C; Kleontas A; Tsilikas C
J Surg Oncol; 2011 Nov; 104(6):654-6. PubMed ID: 21671465
[TBL] [Abstract][Full Text] [Related]
10. Higher complication risk of totally implantable venous access port systems in patients with advanced cancer - a single institution retrospective analysis.
Chang YF; Lo AC; Tsai CH; Lee PY; Sun S; Chang TH; Chen CC; Chang YS; Chen JR
Palliat Med; 2013 Feb; 27(2):185-91. PubMed ID: 22126844
[TBL] [Abstract][Full Text] [Related]
11. [Implantable catheter systems. Experiences with 1000 patients with central venous ports].
Kock HJ; Krause U; Pietsch M; Rasfeld S; Walz MK
Dtsch Med Wochenschr; 1996 Jan; 121(3):47-51. PubMed ID: 8565809
[TBL] [Abstract][Full Text] [Related]
12. Totally implantable central venous access ports in patients with cystic fibrosis: a multicenter prospective cohort study.
Dal Molin A; Di Massimo DS; Braggion C; Bisogni S; Rizzi E; D'Orazio C; Di Toppa MV; Alghisi F; Cristadoro S; Carnovale V; Festa G; Rampini S; Colombo C; Oneta A; Furnari ML; Calamia MA; Zunino ML; Tuccio G; Spadea V; Messore B; Grosso B; Festini F
J Vasc Access; 2012; 13(3):290-5. PubMed ID: 22266592
[TBL] [Abstract][Full Text] [Related]
13. Retrospective evaluation of totally implantable venous access port devices: early and late complications.
Gurkan S; Seber S; Gur O; Yetisyigit T; Okan Donbaloglu M; Ozkaramanli Gur D
J BUON; 2015; 20(1):338-45. PubMed ID: 25778336
[TBL] [Abstract][Full Text] [Related]
14. Long-term experience with a totally implanted catheter system in gynecologic oncologic patients.
Koonings PP; Given FT
J Am Coll Surg; 1994 Feb; 178(2):164-6. PubMed ID: 8173727
[TBL] [Abstract][Full Text] [Related]
15. A peripherally implanted permanent central venous access device.
Morris P; Buller R; Kendall S; Anderson B
Obstet Gynecol; 1991 Dec; 78(6):1138-42. PubMed ID: 1945224
[TBL] [Abstract][Full Text] [Related]
16. Incidence of mechanical malfunction in low-profile subcutaneous implantable venous access devices in patients receiving chemotherapy for gynecologic malignancies.
Subramaniam A; Kim KH; Bryant SA; Kimball KJ; Huh WK; Straughn JM; Estes JM; Alvarez RD
Gynecol Oncol; 2011 Oct; 123(1):54-7. PubMed ID: 21742372
[TBL] [Abstract][Full Text] [Related]
17. Infectious port complications are more frequent in younger patients with hematologic malignancies than in solid tumor patients.
Samaras P; Dold S; Braun J; Kestenholz P; Breitenstein S; Imhof A; Renner C; Stenner-Liewen F; Pestalozzi BC
Oncology; 2008; 74(3-4):237-44. PubMed ID: 18716418
[TBL] [Abstract][Full Text] [Related]
18. [Central venous totally implantable access for high dose chemotherapy in children].
Conter C; Carausu L; Martin E; Rubie H; Castex MP; Marec-Berard P
Arch Pediatr; 2006 Mar; 13(3):256-61. PubMed ID: 16469486
[TBL] [Abstract][Full Text] [Related]
19. Radiologic placement of a low profile implantable venous access port in a pediatric population.
Nosher JL; Bodner LJ; Ettinger LJ; Siegel RL; Gribbin C; Asch J; Drachtman RA
Cardiovasc Intervent Radiol; 2001; 24(6):395-9. PubMed ID: 11907746
[TBL] [Abstract][Full Text] [Related]
20. [Totally implantable venous access ports: frequency of complications and analysis of bacterial contamination after ablation].
Barbut F; Soukouna S; Lalande V; Garcia ML; Neyme D; de Gramont A; Petit JC
Pathol Biol (Paris); 2004 Dec; 52(10):566-74. PubMed ID: 15596304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
